JPWO2021037222A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021037222A5
JPWO2021037222A5 JP2022513891A JP2022513891A JPWO2021037222A5 JP WO2021037222 A5 JPWO2021037222 A5 JP WO2021037222A5 JP 2022513891 A JP2022513891 A JP 2022513891A JP 2022513891 A JP2022513891 A JP 2022513891A JP WO2021037222 A5 JPWO2021037222 A5 JP WO2021037222A5
Authority
JP
Japan
Prior art keywords
cmsd
itams
modified
itam
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547837A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/112182 external-priority patent/WO2021037222A1/en
Publication of JP2022547837A publication Critical patent/JP2022547837A/ja
Publication of JPWO2021037222A5 publication Critical patent/JPWO2021037222A5/ja
Pending legal-status Critical Current

Links

JP2022513891A 2019-08-28 2020-08-28 遺伝子操作されたｔ細胞及びその産生方法 Pending JP2022547837A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/103041 2019-08-28
CN2019103041 2019-08-28
CNPCT/CN2019/125681 2019-12-16
CN2019125681 2019-12-16
PCT/CN2020/112182 WO2021037222A1 (en) 2019-08-28 2020-08-28 Engineered t cells and methods of producing thereof

Publications (2)

Publication Number Publication Date
JP2022547837A JP2022547837A (ja) 2022-11-16
JPWO2021037222A5 true JPWO2021037222A5 (de) 2023-09-01

Family

ID=74683378

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513891A Pending JP2022547837A (ja) 2019-08-28 2020-08-28 遺伝子操作されたｔ細胞及びその産生方法
JP2022513162A Pending JP2022545815A (ja) 2019-08-28 2020-08-28 Ｎｅｆ含有Ｔ細胞及びその産生方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022513162A Pending JP2022545815A (ja) 2019-08-28 2020-08-28 Ｎｅｆ含有Ｔ細胞及びその産生方法

Country Status (11)

Country Link
US (2) US20230085615A2 (de)
EP (2) EP4022044A4 (de)
JP (2) JP2022547837A (de)
KR (2) KR20220066291A (de)
CN (2) CN114599785A (de)
AU (2) AU2020339559A1 (de)
CA (2) CA3150401A1 (de)
IL (1) IL290946A (de)
MX (1) MX2022002325A (de)
TW (2) TW202122575A (de)
WO (2) WO2021037221A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2024092026A1 (en) * 2022-10-25 2024-05-02 Kyverna Therapeutics, Inc. Methods for treating lupus nephritis using anti-cd19 car-t cell therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018132506A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN108395481B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
EP3612275A1 (de) * 2017-04-19 2020-02-26 Allogene Therapeutics, Inc. Verbesserte t-zell-zusammensetzungen und -verfahren
CN109306014B (zh) * 2017-07-27 2022-04-12 上海细胞治疗研究院 一种靶向间皮素的嵌合抗原受体修饰t细胞及其用途
US20190194617A1 (en) * 2017-12-22 2019-06-27 Cell Design Labs, Inc. Single- and multi-chain chimeric antigen receptors
CN111886242A (zh) * 2017-12-29 2020-11-03 纪念斯隆-凯特琳癌症中心 增强的嵌合抗原受体及其用途
WO2019157496A1 (en) * 2018-02-12 2019-08-15 University Of Florida Researchfoundation, Inc. Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a

Similar Documents

Publication Publication Date Title
TWI817302B (zh) 改良的雙特異性多肽分子
WO2021129559A1 (zh) T细胞受体融合蛋白及其用途
Steinle et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family
US20050261478A1 (en) Compositions and methods for regulating lymphocyte activation
EP3472205B1 (de) Chimärer antigen rezeptor
US11198737B2 (en) T cell-antigen coupler with Y177 mutation and methods of uses thereof
DE102006041455B4 (de) Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen
JPH07505282A (ja) キメラ受容体遺伝子およびこれを用いて形質転換した細胞
JP2002512502A (ja) 癌細胞の標的細胞溶解
JPH06319548A (ja) 二特異的融合タンパク質をコードする発現ベクター及び哺乳動物細胞における生物学的に活性な二特異的融合タンパク質の生産方法
Kulemzin et al. Engineering chimeric antigen receptors
JP2020535796A5 (de)
JP2023545907A (ja) 新規共刺激ドメインを含むキメラ抗原受容体及びその使用
JPWO2020228825A5 (de)
JPWO2020228824A5 (de)
JPWO2021037222A5 (de)
WO2022267983A1 (zh) 工程化免疫细胞及其用途
JPWO2020147708A5 (de)
JP2023535485A (ja) 抗ｃｄ２２シングルドメイン抗体および治療用コンストラクト
JPWO2021239812A5 (de)
JPWO2021037221A5 (de)
JPWO2021016585A5 (de)
CN114195898B (zh) 人源化抗cd33的单域抗体及其构建体制备方法和应用
AU773844B2 (en) Compositions and methods for regulating lymphocyte activation
JPWO2021091945A5 (de)